Biomarkers to predict cancer risk in pancreatic IPMN
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial studies whether blood markers can help predict which pancreatic IPMNs are likely to become cancerous. If successful, it could help doctors decide when surgery is needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of IPMN (a type of pancreatic cyst) confirmed by biopsy.
- Full details about your IPMN (type, grade, and if invasive, its stage) must be available.
- Clinical and imaging criteria for surgery from international or European guidelines must be available.
- For cohort B/C: you must have a low burden of other illnesses (Charlson index below 7) and be scheduled for surgery for suspected IPMN.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tissue samples from people having surgery for a suspected pancreatic growth to find markers that might help diagnose pancreatic cancer earlier. By studying the removed tissue, researchers hope to learn more about the earliest changes that lead to cancer.
This study tests a special MRI scan and blood tests to see if they can detect early pancreatic cancer in people with high-risk pancreatic cysts called IPMNs. It may help identify cancer earlier, when treatment is more likely to work.
This trial tests whether an artificial intelligence (AI) system can help doctors spot abnormal or cancerous growths in the pancreas during a special endoscopic procedure called pancreatoscopy. If successful, it could improve the accuracy of detecting these growths and help guide treatment decisions.
This study looks for new markers in the blood or tissues of people with a pancreatic condition called IPMN. The goal is to find better ways to predict if IPMN might turn into cancer and to help choose the best treatment.
This trial looks for markers in cyst fluid and tissue to help identify which IPMN growths are becoming invasive (spreading). It may help doctors decide who needs surgery.
This study looks for “biomarkers,” meaning measurable signs in the blood, in people diagnosed with intraductal papillary mucinous neoplasm (IPMN). It aims to better understand what changes happen in this condition and may help future diagnosis or monitoring.
Hear when a new Intraductal Papillary Mucinous Neoplasm of Pancreas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.